Navigation Links
Invitrogen Launches i-Path -- A Unique Systems Biology Platform at BIO 2005

Scientists in Belgium have discovered how to clone human embryos from eggs that have been matured in the laboratory. Their discovery should make it easier for scientists to create embryonic stem cell lines from cloned embryos and develop them to provide eggs and sperm for infertile couples, the 21st annual conference of the European Society of Human Reproduction and Embryology heard today (Monday 20 June).

Until now, scientists investigating human cloning for therapeutic purposes have been limited to using mature eggs (oocytes) that have reached the metaphase II stage (MII) at which ovulation and fertilisation occurs in humans. However, there are few human MII oocytes available for research because almost all that are retrieved from women seeking fertility treatment are used to treat the patient. Immature oocytes are not used routinely for treatment at present, and so any that are retrieved can be donated for research. These immature oocytes are arrested in the prophase I stage, before meiotic division is complete, when the enlarged nucleus is called the germinal vesicle (GV).

Bjorn Heindryckx, a PhD student at the Infertility Centre at Ghent University Hospital, Belgium, and his colleagues, matured GV oocytes in culture in the laboratory for 44 hours, after which time 85% of the GV oocytes had developed into MII oocytes. From each of these, they removed the nuclear apparatus, which contained the chromosomes that held all the genetic information. Using conventional ICSI techniques, they injected into the empty oocytes the nuclei taken from somatic cumulus1 cells (i.e. non-germ cells) of another person ?a process known as non-autologous nuclear transfer. After time for nuclear re-programming the oocytes were artificially activated by incubation in a medium containing calcium ionophore, which enabled the injected nucleus to prepare for the first embryonic division.

Mr Heindryckx said: "Eighteen out of the 25 in vitro matured MII oocytes survived this nuclear transfer. Of these, 11 showed the formation of one pronucleus. In normal fertilisation the formation of male and female pronuclei is an important stage just before the maternal and paternal chromosomes start to pair up in preparation for the first cell division. In the case of these oocytes they had undergone a pseudo-fertilisation because the pronuclei were derived from whole foreign nuclei, each one with a complete set of homologous [matching] chromosomes, instead of from sperm and eggs which carry only one set of chromosomes each."

Five oocytes divided to the two-cell stage, and of these, three continued to divide to the six- to ten-cell stage. One embryo continued to develop to the compacted stage, when the individual cells started to flatten and increase their contact with one another.

Mr Heindryckx said: "To our knowledge, this is the first report describing the development of cloned human embryos using in vitro matured oocytes and non-autologous transfer via a conventional method of nuclear transfer.

"Our final goal is to use human therapeutic cloning for infertility treatment by creating artificial eggs and sperm for patients who are infertile because of absence or premature loss of eggs or sperm. We would do this by isolating embryonic stem cell lines from cloned early embryos and driving these embryonic stem cells to develop into eggs and sperm in the laboratory."

However, Mr Heindryckx warned that there was a long way to go and many problems to overcome before he and his colleagues could reach their goal.

"None of these early embryos developed to the blastocyst stage, and failure to do so could reveal some problems in gene activation, especially in cloned embryos. So, first we have to understand how to get cloned blastocysts of good quality from in vitro matured oocytes. This will be difficult because it is well known that embryonic development is compromised when in vitro matured oocytes are used, and in cloning technology the oocytes undergo intensive micromanipulation, which makes it even harder to develop good quality blastocysts. Once we have achieved this, the next step will be the isolation of the Inner Cell Mass (ICM) from which we can obtain embryonic stem cells.

"The availability of human oocytes is a major obstacle at the moment for research into therapeutic cloning. Therefore, we consider this research is important because it makes best use of more easily available biological material ?in this case, immature oocytes."


'"/>

Source:Invitrogen


Related biology news :

1. Kinovate Life Sciences Launches Nittophase?High Performance Solid Support For Oligonucleatide Synthesis
2. Affymetrix Launches New Globin-Reduction Kits and Protocol Developed with PreAnalytiX
3. IMF Launches World’s First DNA Database for Myeloma Patients
4. Breast Cancer May Be Uniquely Sensitive To Inhibitors Of PI3K Pathway
5. Unique library of plant genes germinates, takes root at UNC
6. Uniquely human component of language found in gregarious birds
7. Unique equine cataract surgery offered on routine basis
8. Unique dual target specificity of kinase inhibitor key for success against cancer
9. Unique soybean lines hold promise for producing allergy-free soybeans
10. Unique gene regulation gives chilly bugs survival advantage at bottom of the world
11. Unique tomatoes tops in disease-fighting antioxidants
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/29/2016)... BOCA RATON, Florida , March 29, 2016 /PRNewswire/ ... ("LegacyXChange" or the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect ... Synthetic DNA in ink used in a variety of ... preventing theft. Buyers of originally created collectibles from athletes ... authenticity through forensic analysis of the DNA. ...
(Date:3/22/2016)... March 22, 2016 ... Sensors Market for Consumer Industry by Type (Image, ... Application (Communication & IT, Entertainment, Home Appliances, ... Forecast to 2022", published by MarketsandMarkets, the ... to reach USD 26.76 Billion by 2022, ...
(Date:3/21/2016)... 22, 2016 Unique technology ... for superior security   Xura, ... of secure digital communications services, today announced it is ... offer enterprise customers, particularly those in the Financial Services ... voice authentication within a mobile app, alongside, and in ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance Associates® Inc. (RCA), ... free webinar on Performing Quality Investigations: Getting to Root Cause. ... no charge. , Incomplete investigations are still a major concern to the Regulatory ...
Breaking Biology Technology: